Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Samsung BioLogics

https://samsungbiologics.com/

Latest From Samsung BioLogics

Investment Set To Rise, Non-COVID R&D To Normalize As Korean Pharma Looks Ahead To 2022

Scrip takes a look back at the milestone events in the South Korean pharma and biotech industry in 2021 and ahead at what's in store for the coming year, which has kicked off with speculation around a major potential M&A deal.

South Korea Outlook 2022

Coronavirus Update: More Approval, Trial Progress For Non-Vaccine Options

Multiple non-vaccine options for COVID-19 continue to progress, with promising new clinical results for Sorrento's small molecule drug and a supplementary approval in Japan for Chugai's antibody combo. Meanwhile, China's CRDC has in-licensed technology for Ligand to apply to an oral antiviral it is developing. Meanwhile, SK Biosciences' novel nanoparticle vaccine is positive in early trials.

Coronavirus COVID-19 BioPharmaceutical

Leaders Talk Strategy As India Growth Drives Buoyant Sun

Sun Pharma's senior leadership talks to Scrip about the focus in India on differentiated therapies; the challenges of holding adequate 'strategic inventory' amid waves of the pandemic; and where things stand for active pharmaceutical ingredients. India’s top ranked drug firm is apparently not averse to a role in COVID-19 vaccine distribution, either.

Commercial Coronavirus COVID-19

Dawn Of A New Era? Korean Biopharma M&A Landscape Set For Change

Mergers and acquisitions are set to gain momentum in South Korea as firms outside the sector seek new growth engines and more open-minded biopharma companies seek rapid growth and globalization.

South Korea M & A
See All

Company Information

  • Industry
  • Contract Research Organization-CRO
  • Pharmaceuticals
  • Services
UsernamePublicRestriction

Register